US 12,263,210 B2
Immunogenic compounds for cancer therapy
Laurent Chene, Neuville aux Bois (FR); Alban Mathieu, Saint Foy les Lyon (FR); Matthieu Pichaud, Cambridge, MA (US); and Francesco Strozzi, Paris (FR)
Assigned to ENTEROME S.A., Paris (FR)
Filed by ENTEROME S.A., Paris (FR)
Filed on Aug. 30, 2022, as Appl. No. 17/823,117.
Application 17/823,117 is a continuation of application No. 16/338,953, granted, now 11,478,537, previously published as PCT/EP2017/075673, filed on Oct. 9, 2017.
Claims priority of application No. 161929484 (EP), filed on Oct. 7, 2016.
Prior Publication US 2023/0201322 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/385 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 39/385 (2013.01); A61P 35/00 (2018.01); C07K 7/06 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/6031 (2013.01)] 19 Claims
 
1. An immunogenic composition comprising:
(i) an immunogenic compound comprising or consisting of an antigenic peptide off formula (I):
PepNt-CORE-PepCt(I),
wherein:
“PepNt” consists of a polypeptide having an amino acid length varying from 0 to 50 amino acid residues and located at the N-terminal end of the polypeptide off formula (I);
“CORE” consists of a polypeptide consisting of [,] an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, SEQ ID NOs: 53 to 67, and SEQ ID NOs: 69 to 70; and
“PepCt” consists of a polypeptide having an amino acid length varying from 0 to 50 amino acid residues and located at the C-terminal end of the polypeptide of formula (I)
(ii) an antigenic peptide as defined in (i),
(iii) a nanoparticle loaded with at least one immunogenic compound of (i) or at least one antigenic peptide of (ii),
(iv) a cell loaded with at least one immunogenic compound of (i) or at least one antigenic peptide of (ii),
(v) a nucleic acid comprising a polynucleotide encoding (a) the immunogenic compound of (i), wherein the immunogenic compound is a peptide or a protein, or (b) the antigenic peptide of (ii), or
(vi) a host cell comprising the nucleic acid of (v);
wherein the immunogenic composition comprises one or more pharmaceutically acceptable excipients and one or more immunostimulatory agents comprising antigen-presenting cells.